ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Multivalent Vaccines Market Research Report 2025
Published Date: January 2025
|
Report Code: QYRE-Auto-21A9893
Home | Market Reports | Health| Pharmacy
Global Multivalent Vaccines Market Insights Forecast to 2028
BUY CHAPTERS

Global Multivalent Vaccines Market Research Report 2025

Code: QYRE-Auto-21A9893
Report
January 2025
Pages:90
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
GlaxoSmithKline plc. (U.K.)
Pfizer Inc. (US)
Merck & Co., Inc. (US)
Sanofi Pasteur SA (France)
Astellas Pharma Inc. (Japan)
CSL Limited (Australia)
Emergent BioSolutions, Inc (US)
Johnson& Johnson (US)
MedImmune, LLC (US)
Serum Institute of India Pvt. Ltd. (India)
Bavarian Nordic (Denmark)
Mitsubishi Tanabe Pharma Corporation (Japan)
Daiichi Sankyo (Japan)
Protein Sciences Corporation (US)
Panacea Biotec (India)

Multivalent Vaccines Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Multivalent Vaccines Market

Multivalent Vaccines Market

The global market for Multivalent Vaccines was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Multivalent Vaccines, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Multivalent Vaccines.
The Multivalent Vaccines market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Multivalent Vaccines market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Multivalent Vaccines manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Multivalent Vaccines Market Report

Report Metric Details
Report Name Multivalent Vaccines Market
CAGR 5%
Segment by Type
Segment by Application
  • Pediatrics
  • Adults
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company GlaxoSmithKline, plc (U.K.), Pfizer, Inc (US), Merck & Co., Inc (US), Sanofi Pasteur SA (France), Astellas Pharma Inc. (Japan), CSL Limited (Australia), Emergent BioSolutions, Inc (US), Johnson & Johnson (US), MedImmune, LLC (US), Serum Institute of India Pvt. Ltd. (India), Bavarian Nordic (Denmark), Mitsubishi Tanabe Pharma Corporation (Japan), Daiichi Sankyo (Japan), Protein Sciences Corporation (US), Panacea Biotec (India)
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Multivalent Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Multivalent Vaccines in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the Multivalent Vaccines Market report?

Ans: The main players in the Multivalent Vaccines Market are GlaxoSmithKline, plc (U.K.), Pfizer, Inc (US), Merck & Co., Inc (US), Sanofi Pasteur SA (France), Astellas Pharma Inc. (Japan), CSL Limited (Australia), Emergent BioSolutions, Inc (US), Johnson & Johnson (US), MedImmune, LLC (US), Serum Institute of India Pvt. Ltd. (India), Bavarian Nordic (Denmark), Mitsubishi Tanabe Pharma Corporation (Japan), Daiichi Sankyo (Japan), Protein Sciences Corporation (US), Panacea Biotec (India)

What are the Application segmentation covered in the Multivalent Vaccines Market report?

Ans: The Applications covered in the Multivalent Vaccines Market report are Pediatrics, Adults

What are the Type segmentation covered in the Multivalent Vaccines Market report?

Ans: The Types covered in the Multivalent Vaccines Market report are Conjugate Vaccines, Inactivated and Subunit Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, Recombinant Vaccines

Recommended Reports

Vaccine Types

Vaccine Delivery & Packaging

Immunization & Administration

1 Multivalent Vaccines Market Overview
1.1 Product Definition
1.2 Multivalent Vaccines by Type
1.2.1 Global Multivalent Vaccines Market Value Comparison by Type (2024 VS 2031)
1.2.2 Conjugate Vaccines
1.2.3 Inactivated and Subunit Vaccines
1.2.4 Live Attenuated Vaccines
1.2.5 Toxoid Vaccines
1.2.6 Recombinant Vaccines
1.3 Multivalent Vaccines by Application
1.3.1 Global Multivalent Vaccines Market Value by Application (2024 VS 2031)
1.3.2 Pediatrics
1.3.3 Adults
1.4 Global Multivalent Vaccines Market Size Estimates and Forecasts
1.4.1 Global Multivalent Vaccines Revenue 2020-2031
1.4.2 Global Multivalent Vaccines Sales 2020-2031
1.4.3 Global Multivalent Vaccines Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Multivalent Vaccines Market Competition by Manufacturers
2.1 Global Multivalent Vaccines Sales Market Share by Manufacturers (2020-2025)
2.2 Global Multivalent Vaccines Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Multivalent Vaccines Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Multivalent Vaccines, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Multivalent Vaccines, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Multivalent Vaccines, Product Type & Application
2.7 Global Key Manufacturers of Multivalent Vaccines, Date of Enter into This Industry
2.8 Global Multivalent Vaccines Market Competitive Situation and Trends
2.8.1 Global Multivalent Vaccines Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Multivalent Vaccines Players Market Share by Revenue
2.8.3 Global Multivalent Vaccines Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Multivalent Vaccines Market Scenario by Region
3.1 Global Multivalent Vaccines Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Multivalent Vaccines Sales by Region: 2020-2031
3.2.1 Global Multivalent Vaccines Sales by Region: 2020-2025
3.2.2 Global Multivalent Vaccines Sales by Region: 2026-2031
3.3 Global Multivalent Vaccines Revenue by Region: 2020-2031
3.3.1 Global Multivalent Vaccines Revenue by Region: 2020-2025
3.3.2 Global Multivalent Vaccines Revenue by Region: 2026-2031
3.4 North America Multivalent Vaccines Market Facts & Figures by Country
3.4.1 North America Multivalent Vaccines Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Multivalent Vaccines Sales by Country (2020-2031)
3.4.3 North America Multivalent Vaccines Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Multivalent Vaccines Market Facts & Figures by Country
3.5.1 Europe Multivalent Vaccines Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Multivalent Vaccines Sales by Country (2020-2031)
3.5.3 Europe Multivalent Vaccines Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Multivalent Vaccines Market Facts & Figures by Region
3.6.1 Asia Pacific Multivalent Vaccines Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Multivalent Vaccines Sales by Region (2020-2031)
3.6.3 Asia Pacific Multivalent Vaccines Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Multivalent Vaccines Market Facts & Figures by Country
3.7.1 Latin America Multivalent Vaccines Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Multivalent Vaccines Sales by Country (2020-2031)
3.7.3 Latin America Multivalent Vaccines Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Multivalent Vaccines Market Facts & Figures by Country
3.8.1 Middle East and Africa Multivalent Vaccines Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Multivalent Vaccines Sales by Country (2020-2031)
3.8.3 Middle East and Africa Multivalent Vaccines Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Multivalent Vaccines Sales by Type (2020-2031)
4.1.1 Global Multivalent Vaccines Sales by Type (2020-2025)
4.1.2 Global Multivalent Vaccines Sales by Type (2026-2031)
4.1.3 Global Multivalent Vaccines Sales Market Share by Type (2020-2031)
4.2 Global Multivalent Vaccines Revenue by Type (2020-2031)
4.2.1 Global Multivalent Vaccines Revenue by Type (2020-2025)
4.2.2 Global Multivalent Vaccines Revenue by Type (2026-2031)
4.2.3 Global Multivalent Vaccines Revenue Market Share by Type (2020-2031)
4.3 Global Multivalent Vaccines Price by Type (2020-2031)
5 Segment by Application
5.1 Global Multivalent Vaccines Sales by Application (2020-2031)
5.1.1 Global Multivalent Vaccines Sales by Application (2020-2025)
5.1.2 Global Multivalent Vaccines Sales by Application (2026-2031)
5.1.3 Global Multivalent Vaccines Sales Market Share by Application (2020-2031)
5.2 Global Multivalent Vaccines Revenue by Application (2020-2031)
5.2.1 Global Multivalent Vaccines Revenue by Application (2020-2025)
5.2.2 Global Multivalent Vaccines Revenue by Application (2026-2031)
5.2.3 Global Multivalent Vaccines Revenue Market Share by Application (2020-2031)
5.3 Global Multivalent Vaccines Price by Application (2020-2031)
6 Key Companies Profiled
6.1 GlaxoSmithKline, plc (U.K.)
6.1.1 GlaxoSmithKline, plc (U.K.) Company Information
6.1.2 GlaxoSmithKline, plc (U.K.) Description and Business Overview
6.1.3 GlaxoSmithKline, plc (U.K.) Multivalent Vaccines Sales, Revenue and Gross Margin (2020-2025)
6.1.4 GlaxoSmithKline, plc (U.K.) Multivalent Vaccines Product Portfolio
6.1.5 GlaxoSmithKline, plc (U.K.) Recent Developments/Updates
6.2 Pfizer, Inc (US)
6.2.1 Pfizer, Inc (US) Company Information
6.2.2 Pfizer, Inc (US) Description and Business Overview
6.2.3 Pfizer, Inc (US) Multivalent Vaccines Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Pfizer, Inc (US) Multivalent Vaccines Product Portfolio
6.2.5 Pfizer, Inc (US) Recent Developments/Updates
6.3 Merck & Co., Inc (US)
6.3.1 Merck & Co., Inc (US) Company Information
6.3.2 Merck & Co., Inc (US) Description and Business Overview
6.3.3 Merck & Co., Inc (US) Multivalent Vaccines Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Merck & Co., Inc (US) Multivalent Vaccines Product Portfolio
6.3.5 Merck & Co., Inc (US) Recent Developments/Updates
6.4 Sanofi Pasteur SA (France)
6.4.1 Sanofi Pasteur SA (France) Company Information
6.4.2 Sanofi Pasteur SA (France) Description and Business Overview
6.4.3 Sanofi Pasteur SA (France) Multivalent Vaccines Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Sanofi Pasteur SA (France) Multivalent Vaccines Product Portfolio
6.4.5 Sanofi Pasteur SA (France) Recent Developments/Updates
6.5 Astellas Pharma Inc. (Japan)
6.5.1 Astellas Pharma Inc. (Japan) Company Information
6.5.2 Astellas Pharma Inc. (Japan) Description and Business Overview
6.5.3 Astellas Pharma Inc. (Japan) Multivalent Vaccines Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Astellas Pharma Inc. (Japan) Multivalent Vaccines Product Portfolio
6.5.5 Astellas Pharma Inc. (Japan) Recent Developments/Updates
6.6 CSL Limited (Australia)
6.6.1 CSL Limited (Australia) Company Information
6.6.2 CSL Limited (Australia) Description and Business Overview
6.6.3 CSL Limited (Australia) Multivalent Vaccines Sales, Revenue and Gross Margin (2020-2025)
6.6.4 CSL Limited (Australia) Multivalent Vaccines Product Portfolio
6.6.5 CSL Limited (Australia) Recent Developments/Updates
6.7 Emergent BioSolutions, Inc (US)
6.7.1 Emergent BioSolutions, Inc (US) Company Information
6.7.2 Emergent BioSolutions, Inc (US) Description and Business Overview
6.7.3 Emergent BioSolutions, Inc (US) Multivalent Vaccines Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Emergent BioSolutions, Inc (US) Multivalent Vaccines Product Portfolio
6.7.5 Emergent BioSolutions, Inc (US) Recent Developments/Updates
6.8 Johnson & Johnson (US)
6.8.1 Johnson & Johnson (US) Company Information
6.8.2 Johnson & Johnson (US) Description and Business Overview
6.8.3 Johnson & Johnson (US) Multivalent Vaccines Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Johnson & Johnson (US) Multivalent Vaccines Product Portfolio
6.8.5 Johnson & Johnson (US) Recent Developments/Updates
6.9 MedImmune, LLC (US)
6.9.1 MedImmune, LLC (US) Company Information
6.9.2 MedImmune, LLC (US) Description and Business Overview
6.9.3 MedImmune, LLC (US) Multivalent Vaccines Sales, Revenue and Gross Margin (2020-2025)
6.9.4 MedImmune, LLC (US) Multivalent Vaccines Product Portfolio
6.9.5 MedImmune, LLC (US) Recent Developments/Updates
6.10 Serum Institute of India Pvt. Ltd. (India)
6.10.1 Serum Institute of India Pvt. Ltd. (India) Company Information
6.10.2 Serum Institute of India Pvt. Ltd. (India) Description and Business Overview
6.10.3 Serum Institute of India Pvt. Ltd. (India) Multivalent Vaccines Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Serum Institute of India Pvt. Ltd. (India) Multivalent Vaccines Product Portfolio
6.10.5 Serum Institute of India Pvt. Ltd. (India) Recent Developments/Updates
6.11 Bavarian Nordic (Denmark)
6.11.1 Bavarian Nordic (Denmark) Company Information
6.11.2 Bavarian Nordic (Denmark) Description and Business Overview
6.11.3 Bavarian Nordic (Denmark) Multivalent Vaccines Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Bavarian Nordic (Denmark) Multivalent Vaccines Product Portfolio
6.11.5 Bavarian Nordic (Denmark) Recent Developments/Updates
6.12 Mitsubishi Tanabe Pharma Corporation (Japan)
6.12.1 Mitsubishi Tanabe Pharma Corporation (Japan) Company Information
6.12.2 Mitsubishi Tanabe Pharma Corporation (Japan) Description and Business Overview
6.12.3 Mitsubishi Tanabe Pharma Corporation (Japan) Multivalent Vaccines Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Mitsubishi Tanabe Pharma Corporation (Japan) Multivalent Vaccines Product Portfolio
6.12.5 Mitsubishi Tanabe Pharma Corporation (Japan) Recent Developments/Updates
6.13 Daiichi Sankyo (Japan)
6.13.1 Daiichi Sankyo (Japan) Company Information
6.13.2 Daiichi Sankyo (Japan) Description and Business Overview
6.13.3 Daiichi Sankyo (Japan) Multivalent Vaccines Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Daiichi Sankyo (Japan) Multivalent Vaccines Product Portfolio
6.13.5 Daiichi Sankyo (Japan) Recent Developments/Updates
6.14 Protein Sciences Corporation (US)
6.14.1 Protein Sciences Corporation (US) Company Information
6.14.2 Protein Sciences Corporation (US) Description and Business Overview
6.14.3 Protein Sciences Corporation (US) Multivalent Vaccines Sales, Revenue and Gross Margin (2020-2025)
6.14.4 Protein Sciences Corporation (US) Multivalent Vaccines Product Portfolio
6.14.5 Protein Sciences Corporation (US) Recent Developments/Updates
6.15 Panacea Biotec (India)
6.15.1 Panacea Biotec (India) Company Information
6.15.2 Panacea Biotec (India) Description and Business Overview
6.15.3 Panacea Biotec (India) Multivalent Vaccines Sales, Revenue and Gross Margin (2020-2025)
6.15.4 Panacea Biotec (India) Multivalent Vaccines Product Portfolio
6.15.5 Panacea Biotec (India) Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Multivalent Vaccines Industry Chain Analysis
7.2 Multivalent Vaccines Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Multivalent Vaccines Production Mode & Process Analysis
7.4 Multivalent Vaccines Sales and Marketing
7.4.1 Multivalent Vaccines Sales Channels
7.4.2 Multivalent Vaccines Distributors
7.5 Multivalent Vaccines Customer Analysis
8 Multivalent Vaccines Market Dynamics
8.1 Multivalent Vaccines Industry Trends
8.2 Multivalent Vaccines Market Drivers
8.3 Multivalent Vaccines Market Challenges
8.4 Multivalent Vaccines Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
GlaxoSmithKline plc. (U.K.)
Pfizer Inc. (US)
Merck & Co., Inc. (US)
Sanofi Pasteur SA (France)
Astellas Pharma Inc. (Japan)
CSL Limited (Australia)
Emergent BioSolutions, Inc (US)
Johnson& Johnson (US)
MedImmune, LLC (US)
Serum Institute of India Pvt. Ltd. (India)
Bavarian Nordic (Denmark)
Mitsubishi Tanabe Pharma Corporation (Japan)
Daiichi Sankyo (Japan)
Protein Sciences Corporation (US)
Panacea Biotec (India)
List of Tables
 Table 1. Global Multivalent Vaccines Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Multivalent Vaccines Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Multivalent Vaccines Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Multivalent Vaccines Sales (K Pcs) of Key Manufacturers (2020-2025)
 Table 5. Global Multivalent Vaccines Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Multivalent Vaccines Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Multivalent Vaccines Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Multivalent Vaccines Average Price (USD/Pcs) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Multivalent Vaccines, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Multivalent Vaccines, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Multivalent Vaccines, Product Type & Application
 Table 12. Global Key Manufacturers of Multivalent Vaccines, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Multivalent Vaccines by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Multivalent Vaccines as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Multivalent Vaccines Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Multivalent Vaccines Sales by Region (2020-2025) & (K Pcs)
 Table 18. Global Multivalent Vaccines Sales Market Share by Region (2020-2025)
 Table 19. Global Multivalent Vaccines Sales by Region (2026-2031) & (K Pcs)
 Table 20. Global Multivalent Vaccines Sales Market Share by Region (2026-2031)
 Table 21. Global Multivalent Vaccines Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Multivalent Vaccines Revenue Market Share by Region (2020-2025)
 Table 23. Global Multivalent Vaccines Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Multivalent Vaccines Revenue Market Share by Region (2026-2031)
 Table 25. North America Multivalent Vaccines Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Multivalent Vaccines Sales by Country (2020-2025) & (K Pcs)
 Table 27. North America Multivalent Vaccines Sales by Country (2026-2031) & (K Pcs)
 Table 28. North America Multivalent Vaccines Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Multivalent Vaccines Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Multivalent Vaccines Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Multivalent Vaccines Sales by Country (2020-2025) & (K Pcs)
 Table 32. Europe Multivalent Vaccines Sales by Country (2026-2031) & (K Pcs)
 Table 33. Europe Multivalent Vaccines Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Multivalent Vaccines Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Multivalent Vaccines Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Multivalent Vaccines Sales by Region (2020-2025) & (K Pcs)
 Table 37. Asia Pacific Multivalent Vaccines Sales by Region (2026-2031) & (K Pcs)
 Table 38. Asia Pacific Multivalent Vaccines Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Multivalent Vaccines Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Multivalent Vaccines Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Multivalent Vaccines Sales by Country (2020-2025) & (K Pcs)
 Table 42. Latin America Multivalent Vaccines Sales by Country (2026-2031) & (K Pcs)
 Table 43. Latin America Multivalent Vaccines Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Multivalent Vaccines Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Multivalent Vaccines Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Multivalent Vaccines Sales by Country (2020-2025) & (K Pcs)
 Table 47. Middle East and Africa Multivalent Vaccines Sales by Country (2026-2031) & (K Pcs)
 Table 48. Middle East and Africa Multivalent Vaccines Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Multivalent Vaccines Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Multivalent Vaccines Sales (K Pcs) by Type (2020-2025)
 Table 51. Global Multivalent Vaccines Sales (K Pcs) by Type (2026-2031)
 Table 52. Global Multivalent Vaccines Sales Market Share by Type (2020-2025)
 Table 53. Global Multivalent Vaccines Sales Market Share by Type (2026-2031)
 Table 54. Global Multivalent Vaccines Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Multivalent Vaccines Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Multivalent Vaccines Revenue Market Share by Type (2020-2025)
 Table 57. Global Multivalent Vaccines Revenue Market Share by Type (2026-2031)
 Table 58. Global Multivalent Vaccines Price (USD/Pcs) by Type (2020-2025)
 Table 59. Global Multivalent Vaccines Price (USD/Pcs) by Type (2026-2031)
 Table 60. Global Multivalent Vaccines Sales (K Pcs) by Application (2020-2025)
 Table 61. Global Multivalent Vaccines Sales (K Pcs) by Application (2026-2031)
 Table 62. Global Multivalent Vaccines Sales Market Share by Application (2020-2025)
 Table 63. Global Multivalent Vaccines Sales Market Share by Application (2026-2031)
 Table 64. Global Multivalent Vaccines Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Multivalent Vaccines Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Multivalent Vaccines Revenue Market Share by Application (2020-2025)
 Table 67. Global Multivalent Vaccines Revenue Market Share by Application (2026-2031)
 Table 68. Global Multivalent Vaccines Price (USD/Pcs) by Application (2020-2025)
 Table 69. Global Multivalent Vaccines Price (USD/Pcs) by Application (2026-2031)
 Table 70. GlaxoSmithKline, plc (U.K.) Company Information
 Table 71. GlaxoSmithKline, plc (U.K.) Description and Business Overview
 Table 72. GlaxoSmithKline, plc (U.K.) Multivalent Vaccines Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 73. GlaxoSmithKline, plc (U.K.) Multivalent Vaccines Product
 Table 74. GlaxoSmithKline, plc (U.K.) Recent Developments/Updates
 Table 75. Pfizer, Inc (US) Company Information
 Table 76. Pfizer, Inc (US) Description and Business Overview
 Table 77. Pfizer, Inc (US) Multivalent Vaccines Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 78. Pfizer, Inc (US) Multivalent Vaccines Product
 Table 79. Pfizer, Inc (US) Recent Developments/Updates
 Table 80. Merck & Co., Inc (US) Company Information
 Table 81. Merck & Co., Inc (US) Description and Business Overview
 Table 82. Merck & Co., Inc (US) Multivalent Vaccines Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 83. Merck & Co., Inc (US) Multivalent Vaccines Product
 Table 84. Merck & Co., Inc (US) Recent Developments/Updates
 Table 85. Sanofi Pasteur SA (France) Company Information
 Table 86. Sanofi Pasteur SA (France) Description and Business Overview
 Table 87. Sanofi Pasteur SA (France) Multivalent Vaccines Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 88. Sanofi Pasteur SA (France) Multivalent Vaccines Product
 Table 89. Sanofi Pasteur SA (France) Recent Developments/Updates
 Table 90. Astellas Pharma Inc. (Japan) Company Information
 Table 91. Astellas Pharma Inc. (Japan) Description and Business Overview
 Table 92. Astellas Pharma Inc. (Japan) Multivalent Vaccines Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 93. Astellas Pharma Inc. (Japan) Multivalent Vaccines Product
 Table 94. Astellas Pharma Inc. (Japan) Recent Developments/Updates
 Table 95. CSL Limited (Australia) Company Information
 Table 96. CSL Limited (Australia) Description and Business Overview
 Table 97. CSL Limited (Australia) Multivalent Vaccines Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 98. CSL Limited (Australia) Multivalent Vaccines Product
 Table 99. CSL Limited (Australia) Recent Developments/Updates
 Table 100. Emergent BioSolutions, Inc (US) Company Information
 Table 101. Emergent BioSolutions, Inc (US) Description and Business Overview
 Table 102. Emergent BioSolutions, Inc (US) Multivalent Vaccines Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 103. Emergent BioSolutions, Inc (US) Multivalent Vaccines Product
 Table 104. Emergent BioSolutions, Inc (US) Recent Developments/Updates
 Table 105. Johnson & Johnson (US) Company Information
 Table 106. Johnson & Johnson (US) Description and Business Overview
 Table 107. Johnson & Johnson (US) Multivalent Vaccines Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 108. Johnson & Johnson (US) Multivalent Vaccines Product
 Table 109. Johnson & Johnson (US) Recent Developments/Updates
 Table 110. MedImmune, LLC (US) Company Information
 Table 111. MedImmune, LLC (US) Description and Business Overview
 Table 112. MedImmune, LLC (US) Multivalent Vaccines Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 113. MedImmune, LLC (US) Multivalent Vaccines Product
 Table 114. MedImmune, LLC (US) Recent Developments/Updates
 Table 115. Serum Institute of India Pvt. Ltd. (India) Company Information
 Table 116. Serum Institute of India Pvt. Ltd. (India) Description and Business Overview
 Table 117. Serum Institute of India Pvt. Ltd. (India) Multivalent Vaccines Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 118. Serum Institute of India Pvt. Ltd. (India) Multivalent Vaccines Product
 Table 119. Serum Institute of India Pvt. Ltd. (India) Recent Developments/Updates
 Table 120. Bavarian Nordic (Denmark) Company Information
 Table 121. Bavarian Nordic (Denmark) Description and Business Overview
 Table 122. Bavarian Nordic (Denmark) Multivalent Vaccines Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 123. Bavarian Nordic (Denmark) Multivalent Vaccines Product
 Table 124. Bavarian Nordic (Denmark) Recent Developments/Updates
 Table 125. Mitsubishi Tanabe Pharma Corporation (Japan) Company Information
 Table 126. Mitsubishi Tanabe Pharma Corporation (Japan) Description and Business Overview
 Table 127. Mitsubishi Tanabe Pharma Corporation (Japan) Multivalent Vaccines Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 128. Mitsubishi Tanabe Pharma Corporation (Japan) Multivalent Vaccines Product
 Table 129. Mitsubishi Tanabe Pharma Corporation (Japan) Recent Developments/Updates
 Table 130. Daiichi Sankyo (Japan) Company Information
 Table 131. Daiichi Sankyo (Japan) Description and Business Overview
 Table 132. Daiichi Sankyo (Japan) Multivalent Vaccines Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 133. Daiichi Sankyo (Japan) Multivalent Vaccines Product
 Table 134. Daiichi Sankyo (Japan) Recent Developments/Updates
 Table 135. Protein Sciences Corporation (US) Company Information
 Table 136. Protein Sciences Corporation (US) Description and Business Overview
 Table 137. Protein Sciences Corporation (US) Multivalent Vaccines Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 138. Protein Sciences Corporation (US) Multivalent Vaccines Product
 Table 139. Protein Sciences Corporation (US) Recent Developments/Updates
 Table 140. Panacea Biotec (India) Company Information
 Table 141. Panacea Biotec (India) Description and Business Overview
 Table 142. Panacea Biotec (India) Multivalent Vaccines Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 143. Panacea Biotec (India) Multivalent Vaccines Product
 Table 144. Panacea Biotec (India) Recent Developments/Updates
 Table 145. Key Raw Materials Lists
 Table 146. Raw Materials Key Suppliers Lists
 Table 147. Multivalent Vaccines Distributors List
 Table 148. Multivalent Vaccines Customers List
 Table 149. Multivalent Vaccines Market Trends
 Table 150. Multivalent Vaccines Market Drivers
 Table 151. Multivalent Vaccines Market Challenges
 Table 152. Multivalent Vaccines Market Restraints
 Table 153. Research Programs/Design for This Report
 Table 154. Key Data Information from Secondary Sources
 Table 155. Key Data Information from Primary Sources
 Table 156. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Multivalent Vaccines
 Figure 2. Global Multivalent Vaccines Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Multivalent Vaccines Market Share by Type: 2024 & 2031
 Figure 4. Conjugate Vaccines Product Picture
 Figure 5. Inactivated and Subunit Vaccines Product Picture
 Figure 6. Live Attenuated Vaccines Product Picture
 Figure 7. Toxoid Vaccines Product Picture
 Figure 8. Recombinant Vaccines Product Picture
 Figure 9. Global Multivalent Vaccines Market Value by Application (2020-2031) & (US$ Million)
 Figure 10. Global Multivalent Vaccines Market Share by Application: 2024 & 2031
 Figure 11. Pediatrics
 Figure 12. Adults
 Figure 13. Global Multivalent Vaccines Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 14. Global Multivalent Vaccines Market Size (2020-2031) & (US$ Million)
 Figure 15. Global Multivalent Vaccines Sales (2020-2031) & (K Pcs)
 Figure 16. Global Multivalent Vaccines Average Price (USD/Pcs) & (2020-2031)
 Figure 17. Multivalent Vaccines Report Years Considered
 Figure 18. Multivalent Vaccines Sales Share by Manufacturers in 2024
 Figure 19. Global Multivalent Vaccines Revenue Share by Manufacturers in 2024
 Figure 20. Global 5 and 10 Largest Multivalent Vaccines Players: Market Share by Revenue in Multivalent Vaccines in 2024
 Figure 21. Multivalent Vaccines Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 22. Global Multivalent Vaccines Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 23. North America Multivalent Vaccines Sales Market Share by Country (2020-2031)
 Figure 24. North America Multivalent Vaccines Revenue Market Share by Country (2020-2031)
 Figure 25. U.S. Multivalent Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 26. Canada Multivalent Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 27. Europe Multivalent Vaccines Sales Market Share by Country (2020-2031)
 Figure 28. Europe Multivalent Vaccines Revenue Market Share by Country (2020-2031)
 Figure 29. Germany Multivalent Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. France Multivalent Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. U.K. Multivalent Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. Italy Multivalent Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 33. Russia Multivalent Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. Asia Pacific Multivalent Vaccines Sales Market Share by Region (2020-2031)
 Figure 35. Asia Pacific Multivalent Vaccines Revenue Market Share by Region (2020-2031)
 Figure 36. China Multivalent Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. Japan Multivalent Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. South Korea Multivalent Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. India Multivalent Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Australia Multivalent Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Taiwan Multivalent Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Indonesia Multivalent Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Thailand Multivalent Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Malaysia Multivalent Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Philippines Multivalent Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Latin America Multivalent Vaccines Sales Market Share by Country (2020-2031)
 Figure 47. Latin America Multivalent Vaccines Revenue Market Share by Country (2020-2031)
 Figure 48. Mexico Multivalent Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 49. Brazil Multivalent Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 50. Argentina Multivalent Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. Middle East and Africa Multivalent Vaccines Sales Market Share by Country (2020-2031)
 Figure 52. Middle East and Africa Multivalent Vaccines Revenue Market Share by Country (2020-2031)
 Figure 53. Turkey Multivalent Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 54. Saudi Arabia Multivalent Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 55. U.A.E Multivalent Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 56. Global Sales Market Share of Multivalent Vaccines by Type (2020-2031)
 Figure 57. Global Revenue Market Share of Multivalent Vaccines by Type (2020-2031)
 Figure 58. Global Multivalent Vaccines Price (USD/Pcs) by Type (2020-2031)
 Figure 59. Global Sales Market Share of Multivalent Vaccines by Application (2020-2031)
 Figure 60. Global Revenue Market Share of Multivalent Vaccines by Application (2020-2031)
 Figure 61. Global Multivalent Vaccines Price (USD/Pcs) by Application (2020-2031)
 Figure 62. Multivalent Vaccines Value Chain
 Figure 63. Channels of Distribution (Direct Vs Distribution)
 Figure 64. Bottom-up and Top-down Approaches for This Report
 Figure 65. Data Triangulation
 Figure 66. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Seventh Sense AI

SIMILAR REPORTS

Global Multivalent Influenza Vaccines Market Research Report 2025
Global Trivalent Flu Vaccine Market Insights Forecast to 2030
Global Viral Vaccines Market Research Report 2025
Global Attenuated Vaccine Market Research Report 2025
Global Quadrivalent Flu Vaccine Market Insights Forecast to 2030
Global Trivalent Inactivated Influenza Vaccine Market Research Report 2025
Global Vaccine Digital Data Logger Market Insights Forecast to 2030
Global Vaccine Cooler Market Research Report 2025
Vaccines Delivery Devices Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Vaccines Packaging Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Vaccine Combinations Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Nasal Vaccines Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Vaccine Delivery Devices Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Livestock Vaccine Market Research Report 2025
Vaccine Administration Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Influenza A Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global IPV Vaccine Market Research Report 2025
Preventable Vaccines Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Inactivated Polio Virus Vaccine Market Research Report 2025
Vaccine Glass Vials Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

RELATED REPORTS

Global GLP-1 Targeted Peptide Weight Loss Drugs Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-19A18322
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Stimulant-Free Fat Burners Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-3E3525
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Test Boosters Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-35T3049
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Salsalate Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-33Y1801
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions